Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.48) per share which met the analyst consensus estimate. This is a 23.81 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $5.65 million which beat the analyst consensus estimate of $3.12 million by 81.09 percent. This is a 107.80 percent increase over sales of $2.72 million the same period last year.